<p>2025 年 3 月 31 日- 下午 6:08</p>
<p>俄亥俄州哥伦布市 --（商业资讯）--Navidea Biopharmaceuticals, Inc.（“Navidea” 或 “公司”）今天宣布，其董事会已决定延长公司的第 382 条权利协议（“第 382 条权利计划”）。该计划最初于 2022 年 4 月 7 日通过，原定于 2025 年 4 月 6 日到期，现在已延长至 2027 年 4 月 7 日。</p>
<p>第 382 条权利计划旨在保护 Navidea 利用其净经营损失结转（“NOLs”）和其他税务资产的能力。截至 2024 年 12 月 31 日，Navidea 在美国联邦 NOLs 中约有 1.7 亿美元，以及约 900 万美元的研发税收抵免，可用于抵消未来的应税收入。然而，如果公司经历了《国内税收法》第 382 条所定义的 “所有权变更”，这些有价值的税务属性可能会受到显著限制。一般而言，所有权变更发生在 Navidea 的 “5% 股东” 集体持股在滚动三年内增加超过 50 个百分点时。</p>
<p>为了帮助防止此类事件的发生，第 382 条权利计划阻止任何个人或团体获得 Navidea 已发行普通股 4.99% 或更多的实益所有权。根据该计划，在最初通过时，董事会宣布每股 Navidea 普通股将分配一份优先股购买权。该权利仅在某人或某团体获得 Navidea 普通股 4.99% 或更多时才可行使。</p>
<p>如果权利被触发，所有股东（收购方除外）将有权以 50% 的折扣购买股份，或者 Navidea 可以将每份权利兑换为五股普通股。董事会保留酌情授予豁免的权力。</p>
<p>Navidea 的首席财务官 Craig Dais 评论道：“延长第 382 条权利计划确保我们继续保护我们重要的 NOLs，这是公司未来的关键财务资产。”</p>
<p>关于 Navidea</p>
<p>Navidea Biopharmaceuticals, Inc.（OTC: NAVB）是一家生物制药公司，专注于精准免疫诊断剂和免疫治疗药物的开发。Navidea 正在基于其 Manocept 平台开发多种精准靶向产品，以通过识别疾病的部位和途径来增强患者护理，并实现更好的诊断准确性、临床决策和靶向治疗。Navidea 的 Manocept 平台基于能够特异性靶向在活化巨噬细胞上表达的 CD206 甘露糖受体。Manocept 平台是 Navidea 基于该平台开发和商业化的首个产品 Tc99m tilmanocept 的分子基础。Navidea 的战略是通过推出新产品和推进公司的管道，通过全球合作和商业化努力实现卓越的增长和股东回报。有关更多信息，请访问 www.navidea.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的前瞻性声明。我们在很大程度上基于当前的预期和关于影响我们业务财务状况的未来事件和财务趋势的预测来制定这些前瞻性声明。前瞻性声明包括我们对待决诉讼和其他事项的预期。这些前瞻性声明受到多种风险、不确定性和假设的影响，包括但不限于：我们经营亏损的历史和未来盈利能力的不确定性；任何待决诉讼的最终结果；我们成功完成药物候选者的研究和进一步开发的能力；获得药物候选者的监管批准的时间、成本和不确定性；我们成功商业化药物候选者的能力；对特许权使用费和补助收入的依赖；我们实施增长战略的能力；我们业务的预期趋势；我们有限的产品线和分销渠道；技术的进步和新竞争产品的发展；我们维持有效的财务报告内部控制的能力；当前冠状病毒大流行的影响；以及我们最近的 10-K 表格年报和其他 SEC 文件中详细列出的其他风险因素。我们强烈建议您仔细审查和考虑我们在 SEC 文件中找到的披露，这些文件可在 http://www.sec.gov 或 http://ir.navidea.com 获取。</p>
<p>投资者被敦促考虑包含 “将”、“可能”、“能够”、“应该”、“计划”、“继续”、“设计”、“目标”、“预测”、“未来”、“相信”、“打算”、“期望”、“预期”、“估计”、“项目” 和类似表达的声明，以及这些词的否定形式或其他可比词，作为不确定的前瞻性声明。</p>
<p>您被警告不要对任何前瞻性声明过度依赖，这些声明可能会被证明是错误的。我们没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，在本报告日期之后。鉴于这些风险和不确定性，本报告中讨论的前瞻性事件和情况可能不会发生，实际结果可能与预期或暗示的前瞻性声明有重大差异。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTAzMzE4MjI1MzhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTAzMzE4MjI1MzhyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20250331822538/en/</p>
<p><strong>投资者关系联系人</strong></p>
<p>Navidea Biopharmaceuticals, Inc.</p>
<p>克雷格·A·戴斯，首席财务官</p>
<p>cdais@navidea.com</p>
<p>(614)-822-2322</p>
<p>来源：Navidea Biopharmaceuticals, Inc.</p>

Navidea生物制药

NAVBQ

<p>Navidea 生物制药已将其第 382 条权利协议的有效期延长至 2027 年 4 月 7 日，原定于 2025 年到期。该计划旨在保护公司的净经营亏损结转（NOLs）和税务资产，合计约为 1.7 亿美元的美国联邦 NOLs 和 900 万美元的研发税收抵免。该计划通过防止任何个人或团体获得公司 4.99% 或更多的股份，来阻止可能限制这些税收优惠的所有权变更。首席财务官 Craig Dais 强调了这一延期对公司财务未来的重要性</p>

<p>03/31/2025 - 06:08 PM</p>
<div class="lb-trans"><p>2025 年 3 月 31 日- 下午 6:08</p>
</div><p>COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company’s Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027.</p>
<div class="lb-trans"><p>俄亥俄州哥伦布市 --（商业资讯）--Navidea Biopharmaceuticals, Inc.（“Navidea” 或 “公司”）今天宣布，其董事会已决定延长公司的第 382 条权利协议（“第 382 条权利计划”）。该计划最初于 2022 年 4 月 7 日通过，原定于 2025 年 4 月 6 日到期，现在已延长至 2027 年 4 月 7 日。</p>
</div><p>The Section 382 Rights Plan is designed to safeguard Navidea’s ability to utilize its net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&amp;D tax credits that may be used to offset future taxable income. However, these valuable tax attributes could be significantly limited if the Company experiences an “ownership change” as defined by Section 382 of the Internal Revenue Code. Generally, an ownership change occurs if the collective ownership of Navidea’s stock by its “5-percent shareholders” increases by more than 50 percentage points over a rolling three-year period.</p>
<div class="lb-trans"><p>第 382 条权利计划旨在保护 Navidea 利用其净经营损失结转（“NOLs”）和其他税务资产的能力。截至 2024 年 12 月 31 日，Navidea 在美国联邦 NOLs 中约有 1.7 亿美元，以及约 900 万美元的研发税收抵免，可用于抵消未来的应税收入。然而，如果公司经历了《国内税收法》第 382 条所定义的 “所有权变更”，这些有价值的税务属性可能会受到显著限制。一般而言，所有权变更发生在 Navidea 的 “5% 股东” 集体持股在滚动三年内增加超过 50 个百分点时。</p>
</div><p>To help prevent such an event, the Section 382 Rights Plan discourages any individual or group from acquiring beneficial ownership of 4.99% or more of Navidea’s outstanding common stock. Under the plan, when originally adopted, the Board declared a dividend of one preferred share purchase right for each share of Navidea common stock outstanding as of the close of business on April 12, 2022. The rights will become exercisable only if a person or group acquires 4.99% or more of Navidea’s common stock.</p>
<div class="lb-trans"><p>为了帮助防止此类事件的发生，第 382 条权利计划阻止任何个人或团体获得 Navidea 已发行普通股 4.99% 或更多的实益所有权。根据该计划，在最初通过时，董事会宣布每股 Navidea 普通股将分配一份优先股购买权。该权利仅在某人或某团体获得 Navidea 普通股 4.99% 或更多时才可行使。</p>
</div><p>If the rights are triggered, all shareholders—except for the acquiring party—will be entitled to purchase shares at a 50% discount or, alternatively, Navidea may exchange each right for five shares of common stock. The Board retains the authority to grant exemptions at its discretion.</p>
<div class="lb-trans"><p>如果权利被触发，所有股东（收购方除外）将有权以 50% 的折扣购买股份，或者 Navidea 可以将每份权利兑换为五股普通股。董事会保留酌情授予豁免的权力。</p>
</div><p>Craig Dais, Navidea’s Chief Financial Officer, commented, “Extending the Section 382 Rights Plan ensures we continue to protect our significant NOLs, a key financial asset for the Company’s future.”</p>
<div class="lb-trans"><p>Navidea 的首席财务官 Craig Dais 评论道：“延长第 382 条权利计划确保我们继续保护我们重要的 NOLs，这是公司未来的关键财务资产。”</p>
</div><p>About Navidea</p>
<div class="lb-trans"><p>关于 Navidea</p>
</div><p>Navidea Biopharmaceuticals, Inc. (OTC: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.（OTC: NAVB）是一家生物制药公司，专注于精准免疫诊断剂和免疫治疗药物的开发。Navidea 正在基于其 Manocept 平台开发多种精准靶向产品，以通过识别疾病的部位和途径来增强患者护理，并实现更好的诊断准确性、临床决策和靶向治疗。Navidea 的 Manocept 平台基于能够特异性靶向在活化巨噬细胞上表达的 CD206 甘露糖受体。Manocept 平台是 Navidea 基于该平台开发和商业化的首个产品 Tc99m tilmanocept 的分子基础。Navidea 的战略是通过推出新产品和推进公司的管道，通过全球合作和商业化努力实现卓越的增长和股东回报。有关更多信息，请访问 www.navidea.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.</p>
<div class="lb-trans"><p>本新闻稿包含根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的前瞻性声明。我们在很大程度上基于当前的预期和关于影响我们业务财务状况的未来事件和财务趋势的预测来制定这些前瞻性声明。前瞻性声明包括我们对待决诉讼和其他事项的预期。这些前瞻性声明受到多种风险、不确定性和假设的影响，包括但不限于：我们经营亏损的历史和未来盈利能力的不确定性；任何待决诉讼的最终结果；我们成功完成药物候选者的研究和进一步开发的能力；获得药物候选者的监管批准的时间、成本和不确定性；我们成功商业化药物候选者的能力；对特许权使用费和补助收入的依赖；我们实施增长战略的能力；我们业务的预期趋势；我们有限的产品线和分销渠道；技术的进步和新竞争产品的发展；我们维持有效的财务报告内部控制的能力；当前冠状病毒大流行的影响；以及我们最近的 10-K 表格年报和其他 SEC 文件中详细列出的其他风险因素。我们强烈建议您仔细审查和考虑我们在 SEC 文件中找到的披露，这些文件可在 http://www.sec.gov 或 http://ir.navidea.com 获取。</p>
</div><p>Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.</p>
<div class="lb-trans"><p>投资者被敦促考虑包含 “将”、“可能”、“能够”、“应该”、“计划”、“继续”、“设计”、“目标”、“预测”、“未来”、“相信”、“打算”、“期望”、“预期”、“估计”、“项目” 和类似表达的声明，以及这些词的否定形式或其他可比词，作为不确定的前瞻性声明。</p>
</div><p>You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward- looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.</p>
<div class="lb-trans"><p>您被警告不要对任何前瞻性声明过度依赖，这些声明可能会被证明是错误的。我们没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，在本报告日期之后。鉴于这些风险和不确定性，本报告中讨论的前瞻性事件和情况可能不会发生，实际结果可能与预期或暗示的前瞻性声明有重大差异。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTAzMzE4MjI1MzhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250331822538r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250331822538/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20250331822538/en/</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong></p>
</div><p>Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.</p>
</div><p>Craig A. Dais, Chief Financial Officer</p>
<div class="lb-trans"><p>克雷格·A·戴斯，首席财务官</p>
</div><p>cdais@navidea.com</p>
<div class="lb-trans"><p>cdais@navidea.com</p>
</div><p>(614)-822-2322</p>
<div class="lb-trans"><p>(614)-822-2322</p>
</div><p>Source: Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Navidea Biopharmaceuticals, Inc.</p>
</div>

Navidea 生物制药公司宣布延长一项旨在保护净营运亏损（NOLs）和其他税收资产的计划 | NAVB 股票新闻